| Accelerate Resources Limited (AX8) ORDINARY FULLY PAID |
Materials |
$6 |
Proposed issue of securities - AX8
|
28 May 2026 9:52AM |
$0.007 |
$0.005 |
fallen by
28.57%
|
|
| VRX Silica Limited (VRX) ORDINARY FULLY PAID |
Materials |
$31 |
Entitlement Offer Prospectus
|
28 May 2026 9:52AM |
$0.041 |
$0.040 |
fallen by
2.44%
|
|
VRX - Price-sensitive ASX Announcement
Full Release
Key Points
- Entitlement Offer to raise up to $6,232,199
- Offer price of $0.04 per share
- Entitlement Offer Ratio of 1:5
- Minimum subscription set at $2,000,000
- Purpose includes early works and engineering at Arrowsmith North
- Additional funds towards Arramall property and Muchea studies
- Directors' interests and potential dilution risks outlined
- Key dates: Announcement on 27 May 2026, Closing on 19 June 2026
- Underwriting Options to be issued with ratio 3:$1
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Accelerate Resources Limited (AX8) ORDINARY FULLY PAID |
Materials |
$6 |
Proposed issue of securities - AX8
|
28 May 2026 9:52AM |
$0.007 |
$0.005 |
fallen by
28.57%
|
|
| Accelerate Resources Limited (AX8) ORDINARY FULLY PAID |
Materials |
$6 |
AX8 Raises $2M to Advance Gold and Manganese Projects
|
28 May 2026 9:52AM |
$0.007 |
$0.005 |
fallen by
28.57%
|
|
AX8 - Price-sensitive ASX Announcement
Full Release
Key Points
- Accelerate Resources Limited raised A$2.0 million through a two-tranche share placement.
- The funds will support exploration at the Balagundi Gold Project and Woodie Woodie North Manganese Project.
- The placement price was set at A$0.005 per new share.
- The first tranche will settle approximately A$1.2 million, with the second A$0.8 million subject to shareholder approval.
- The company's CEO and board directors will contribute A$75,000 subject to shareholder approval.
- Field programs and results are anticipated across both gold and manganese projects in the upcoming months.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Strata Minerals Limited (SMX) ORDINARY FULLY PAID |
Materials |
$8 |
Trading Halt
|
28 May 2026 9:52AM |
$0.015 |
$0.019 |
risen by
26.67%
|
|
SMX - Price-sensitive ASX Announcement
Full Release
Key Points
- Trading halt for Strata Minerals Limited (ASX: SMX) initiated.
- Pending announcement about a mining services agreement for Zelica Gold Project.
- Halt effective from 28 May 2026 until 1 June 2026 or upon announcement release.
- Request made under ASX Listing Rule 17.1.
- Directors unaware of reasons against the trading halt.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Actinogen Medical Limited (ACW) ORDINARY FULLY PAID |
Health Care |
$124 |
Actinogen receives positive scientific advice from EMA
|
28 May 2026 9:51AM |
$0.038 |
$0.034 |
fallen by
10.53%
|
|
ACW - Price-sensitive ASX Announcement
Full Release
Key Points
- Actinogen Medical Limited received positive scientific advice from the European Medicines Agency (EMA).
- The advice aligns with prior guidance from the U.S. FDA for their Alzheimer's disease program.
- EMA and Actinogen agreed on the regulatory requirements for Xanamem®, including the design of a pivotal clinical trial.
- The EMA prefers broader inclusion criteria for the trial, encompassing more patients with moderate Alzheimer's.
- Actinogen has conducted extensive studies on Xanamem's safety and efficacy, with over 500 participants in various trials.
- Xanamem is designed to regulate cortisol in the brain, which is associated with cognitive decline in Alzheimer's.
- The results from these trials are expected to provide pivotal data for future marketing applications in the EU.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Terragen Holdings Limited (TGH) ORDINARY FULLY PAID |
Materials |
$17 |
Terragen Secures 1st Commercial Feedlot, Mort & Co Update
|
28 May 2026 9:51AM |
$0.016 |
$0.021 |
risen by
31.25%
|
|
TGH - Price-sensitive ASX Announcement
Full Release
Key Points
- Terragen secures first large-scale commercial supply agreement.
- Agreement with Ravensworth Feedlot, NSW for TPR and GLP products.
- Minimum commitment of 360,000 doses of TPR.
- Agreement includes the installation of a Terragen dispenser.
- If successful, the trial with Mort & Co may boost TPR sales in FY2027.
- Trial supported by Meat & Livestock Australia Donor Company.
- Potential 25% to 50% sales increase in early 2027 contingent on KPI achievement.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Viking Mines Limited (VKA) ORDINARY FULLY PAID |
Materials |
$27 |
LINKA METALLURGY SUCCESS DELIVERS 62.5%WO3 AT 59.8% RECOVERY
|
28 May 2026 9:50AM |
$0.011 |
$0.011 |
fallen by
0%
|
|
VKA - Price-sensitive ASX Announcement
Full Release
Key Points
- Premium 62.5% WO3 concentrate achieved at 59.8% recovery from 1.2% WO3 feed grade.
- Significant improvement from previous results, increasing from 46.0% recovery to 59.8%.
- The testwork validates a low-CAPEX gravity-led flowsheet strategy.
- Testwork carried out on a larger 10 kg sample.
- Ongoing refinements and improvements in the flotation stage.
- Linka Project is advancing towards maiden drilling programme in June 2026 quarter.
- Strategic positioning as a US-based scheelite producer amid high tungsten prices.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Gold Hydrogen Limited (GHY) ORDINARY FULLY PAID |
Energy |
$78 |
Shareholder and Investor Update Presentation
|
28 May 2026 9:49AM |
$0.485 |
$0.430 |
fallen by
11.34%
|
|
| Nexalis Therapeutics Ltd (NX1) ORDINARY FULLY PAID |
Health Care |
$5 |
Reinstatement to Official Quotation
|
28 May 2026 9:48AM |
$0.025 |
$0.020 |
fallen by
20%
|
|
NX1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Reinstatement to official quotation on the ASX.
- Suspension of trading lifted for Nexalis Therapeutics Ltd.
- Announcement related to existing debt facility.
- ASX compliance issued the reinstatement.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Nexalis Therapeutics Ltd (NX1) ORDINARY FULLY PAID |
Health Care |
$5 |
Binding Letter of Intent to replace existing $53m facility
|
28 May 2026 9:48AM |
$0.025 |
$0.020 |
fallen by
20%
|
|
NX1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Nexalis Therapeutics Ltd has signed a binding letter of intent with Point8 Capital to replace its existing $53 million Linlithgow Family Office facility.
- The new funding facility, known as the Point8 Facility, will provide up to $53 million in non-dilutive funding.
- The funding is structured across three sub-facilities dedicated to Nexalis’ core clinical programs: IRX-211, IRX-616a, and IRX-SRX25.
- Funding from the Point8 Facility will be used for approved research activities, including costs related to clinical trials.
- Point8 Capital will receive 49.35 million options as part of the equity participation for the lender.
- The options will be structured to be exercised in three tranches aligned with each of Nexalis’s clinical programs, potentially exercisable when each program is Phase 3 ready.
- The interest rate of the new facility is set at 15% per annum, capitalized monthly, with an additional 5% in case of default.
- The facility includes a general security deed over all assets and undertakings of Nexalis.
- The previous LFO Facility was terminated, with only $0.8 million of the $2.4 million requested being received.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Sunshine Metals Limited (SHN) ORDINARY FULLY PAID |
Materials |
$102 |
Change of Director's Interest Notice
|
28 May 2026 9:48AM |
$0.038 |
$0.029 |
fallen by
23.68%
|
|
| BPH Global Ltd (BP8) ORDINARY FULLY PAID |
Health Care |
$4 |
Strong seaweed trading results A$3.33M over first 12 months
|
28 May 2026 9:47AM |
$0.002 |
$0.002 |
fallen by
25%
|
|
BP8 - Price-sensitive ASX Announcement
Full Release
Key Points
- BPH Global Ltd recorded gross sales of IDR 4,965,000,000 for the twelfth trading period.
- The twelfth month trading result is the second highest monthly result to date.
- Total gross sales over the first twelve months reached approximately A$3.33 million.
- Improved trading conditions due to the end of the monsoon season in Makassar.
- Stable customer demand in both domestic and export markets.
- Future financial reporting will transition to calendar month basis.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Solis Minerals Ltd (SLM) ORDINARY FULLY PAID |
Materials |
$42 |
Webinar - Drill Preparations for Brazil Lithium Project
|
28 May 2026 9:47AM |
$0.105 |
$0.130 |
risen by
23.81%
|
|
| Emyria Limited (EMD) ORDINARY FULLY PAID |
Health Care |
$34 |
TGA Update to Accelerate Empax Therapist Recruitment
|
28 May 2026 9:46AM |
$0.040 |
$0.042 |
risen by
5%
|
|
EMD - Price-sensitive ASX Announcement
Full Release
Key Points
- TGA updates broaden recruitment profile for Emyria's Empax clinics.
- Expanded therapist eligibility to include diverse disciplines and support culturally safe care.
- Expected benefits in clinic utilization, therapist recruitment, and patient access by H2 CY2026.
- Final endorsement by TGA awaited, with workforce planning and training underway.
- Positive step reflecting growing evidence and experience with psychedelic-assisted psychotherapy.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| United Overseas Australia Limited (UOS) ORDINARY FULLY PAID |
Real Estate |
$249 |
Trading Halt
|
28 May 2026 9:44AM |
$0.665 |
$0.695 |
risen by
4.51%
|
|
UOS - Price-sensitive ASX Announcement
Full Release
Key Points
- Trading halt requested by United Overseas Australia Ltd.
- Halt related to Board and Management composition announcement.
- Securities halted until announcement or 1 June 2026.
- No known reasons for not granting the halt.
- No additional information about the halt.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Li-FT Power Ltd (LFT) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$117 |
Replacement Corporate Governance Statement
|
28 May 2026 9:44AM |
$5.780 |
$4.540 |
fallen by
21.45%
|
|
| Aspermont Limited (ASP) ORDINARY FULLY PAID |
Communication Services |
$20 |
Half Year Results Presentation
|
28 May 2026 9:43AM |
$1.900 |
$1.730 |
fallen by
8.95%
|
|
| Westar Resources Limited (WSR) ORDINARY FULLY PAID |
Materials |
$6 |
Initial Director's Interest Notice
|
28 May 2026 9:42AM |
$0.007 |
$0.007 |
fallen by
0%
|
|
| Alternative Investment Trust (AIQ) ORDINARY UNITS FULLY PAID |
Financials |
$83 |
Notification of cessation of securities - AIQ
|
28 May 2026 9:42AM |
$1.380 |
$1.385 |
risen by
0.36%
|
|
| Westar Resources Limited (WSR) ORDINARY FULLY PAID |
Materials |
$6 |
Final Director's Interest Notice
|
28 May 2026 9:41AM |
$0.007 |
$0.007 |
fallen by
0%
|
|
| Imugene Limited (IMU) ORDINARY FULLY PAID |
Health Care |
$38 |
First Patient in BTKi Combination Cohort of azer-cel study
|
28 May 2026 9:41AM |
$0.110 |
$0.091 |
fallen by
17.27%
|
|
IMU - Price-sensitive ASX Announcement
Full Release
Key Points
- Imugene has dosed the first patient in the BTKi combination cohort of the azer-cel Phase 1b study.
- The study is being conducted at Baylor University, Texas.
- The patient has Mantle Cell Lymphoma and failed prior BTKi therapy.
- The combination aims to improve the activity of azer-cel with BTKi.
- The global BTKi market was valued at approximately US$12.0 billion in 2025.
- The trial includes sites in the US and Australia.
- The study explores the safety and preliminary efficacy of the combination treatment.
- Updates will be provided as patients become evaluable and data matures.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Southern Palladium Limited (SPD) ORDINARY FULLY PAID |
Materials |
$159 |
Change of Director's Interest Notice - Roger Baxter
|
28 May 2026 9:41AM |
$1.560 |
$1.200 |
fallen by
23.08%
|
|
| Aspermont Limited (ASP) ORDINARY FULLY PAID |
Communication Services |
$20 |
Half Yearly Report and Accounts
|
28 May 2026 9:41AM |
$1.900 |
$1.730 |
fallen by
8.95%
|
|
| Amcor Plc (AMC) CDI 1:1 FOREIGN EXEMPT NYSE |
Materials |
$8,193 |
Form SD
|
28 May 2026 9:41AM |
$53.840 |
$56.870 |
risen by
5.63%
|
|
Call 1300 880 160
Start a chat
Schedule a call
